MDxHealth SA Share Price Euronext Bruxelles
Stocks
MDXH
BE0974461940
Biotechnology & Medical Research
| Market Cap | 51.14M 57.23M 47.71M 43.33M 81.61M 5.54B 82.22M 573M 224M 2.82B 215M 210M 9.05B | P/E 2026 * |
-1.17x | P/E 2027 * | -2.1x |
|---|---|---|---|---|---|
| Enterprise Value | 172M 192M 160M 146M 274M 18.61B 276M 1.93B 753M 9.46B 722M 707M 30.42B | EV / Sales 2026 * |
1.79x | EV / Sales 2027 * | 1.74x |
| Free-Float |
77.86% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: MDxHealth SA
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 64 | 17/02/2019 | |
Ron Kalfus
DFI | Director of Finance/CFO | 52 | 21/07/2019 |
Miriam Reyes
COO | Chief Operating Officer | - | - |
| Director | Title | Age | Since |
|---|---|---|---|
Hilde Windels
BRD | Director/Board Member | 61 | 31/10/2017 |
Koen Hoffman
CHM | Chairman | 58 | 31/12/2017 |
| Director/Board Member | 64 | 17/02/2019 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -.--% | -2.58% | - | - | 57.24M | |
| +4.16% | +4.16% | +49.37% | +94.17% | 74.69B | |
| +0.46% | -0.97% | +23.51% | +79.34% | 58.81B | |
| +0.17% | +0.35% | +6.85% | +34.55% | 48.45B | |
| +0.50% | -2.14% | +331.33% | +702.20% | 42.84B | |
| -0.72% | -3.99% | +28.50% | +29.94% | 42.79B | |
| +0.34% | -0.52% | +6.56% | +109.35% | 41.25B | |
| -0.11% | +1.96% | +9.19% | +52.66% | 31.13B | |
| -2.07% | +1.16% | +35.00% | +26.28% | 30.28B | |
| -0.50% | -3.10% | -10.19% | -14.35% | 24.05B | |
| Average | +0.22% | -0.25% | +53.35% | +123.79% | 43.81B | |
| Weighted average by Cap. | +0.69% | -0.50% | +56.27% | +130.20% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 96.12M 108M 89.68M 81.46M 153M 10.41B 155M 1.08B 421M 5.29B 404M 395M 17.01B | 109M 122M 102M 92.23M 174M 11.78B 175M 1.22B 477M 5.99B 457M 447M 19.26B |
| Net income | -29.64M -33.17M -27.65M -25.12M -47.31M -3.21B -47.66M -332M -130M -1.63B -125M -122M -5.25B | -18.12M -20.28M -16.91M -15.36M -28.92M -1.96B -29.14M -203M -79.37M -998M -76.13M -74.49M -3.21B |
| Net Debt | 121M 135M 113M 102M 193M 13.07B 194M 1.35B 529M 6.65B 507M 496M 21.37B | 139M 155M 129M 118M 221M 15.02B 223M 1.55B 607M 7.64B 583M 570M 24.55B |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
